Patients with advanced gastric cancer and positive peritoneal cytology and/or peritoneal dissemination are deemed to be incurable and to hold dismal prognosis. So far, the only treatment option for these patients has been palliative systemic (chemo)therapy. However, for the last three decades, great progress has been made in attempts to treat (potential) peritoneal dissemination by means of complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) after preoperative systemic therapy. This review is focused on the recent achievements of this multimodal strategy. Additionally, the review stands as background for the 4th International Conference “Advances in Surgical Oncology” that was held at the Medical U...
Peritoneal metastases from gastrointestinal cancers remain a morbid and fatal disease entity, reflec...
Gastric cancer (GC) patients with peritoneal metastasis tend to achieve poor clinical out-comes. Unt...
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in intra...
Abstract Ashwin K.R. ...
This thesis focuses on the treatment of peritoneal metastases of gastric and colorectal cancer, spec...
Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive tr...
Peritoneal Carcinomatosis (PC) from metastasization of Gastric Cancer (GC), either present at first ...
Peritoneal carcinomatosis (PC) from gastric cancer is a condition with a very bleak prognosis. Most ...
The number of new gastric cancer (GC) cases is decreasing, and these patients have longer survival t...
Background and Objectives: Clinical experience in Western Europe suggests that cytoreductive surgery...
Background The development of multimodality treatment, including cytoreductive surgery (CRS) with he...
Background Patients with peritoneal metastases of gastric cancer have a poor prognosis with a median...
Background: The development of multimodality treatment, including cytoreductive surgery (CRS) with h...
Due to limited systemic treatment options, peritoneal carcinomatosis of gastric origin is still asso...
Peritoneal carcinomatosis (PC) had long been regarded as a terminal disease, characterized by a very...
Peritoneal metastases from gastrointestinal cancers remain a morbid and fatal disease entity, reflec...
Gastric cancer (GC) patients with peritoneal metastasis tend to achieve poor clinical out-comes. Unt...
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in intra...
Abstract Ashwin K.R. ...
This thesis focuses on the treatment of peritoneal metastases of gastric and colorectal cancer, spec...
Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive tr...
Peritoneal Carcinomatosis (PC) from metastasization of Gastric Cancer (GC), either present at first ...
Peritoneal carcinomatosis (PC) from gastric cancer is a condition with a very bleak prognosis. Most ...
The number of new gastric cancer (GC) cases is decreasing, and these patients have longer survival t...
Background and Objectives: Clinical experience in Western Europe suggests that cytoreductive surgery...
Background The development of multimodality treatment, including cytoreductive surgery (CRS) with he...
Background Patients with peritoneal metastases of gastric cancer have a poor prognosis with a median...
Background: The development of multimodality treatment, including cytoreductive surgery (CRS) with h...
Due to limited systemic treatment options, peritoneal carcinomatosis of gastric origin is still asso...
Peritoneal carcinomatosis (PC) had long been regarded as a terminal disease, characterized by a very...
Peritoneal metastases from gastrointestinal cancers remain a morbid and fatal disease entity, reflec...
Gastric cancer (GC) patients with peritoneal metastasis tend to achieve poor clinical out-comes. Unt...
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in intra...